An infectious SARS-CoV-2 B.1.1.529 Omicron virus escapes neutralization by therapeutic monoclonal antibodies

• Published in: Nature medicine Vol. 28; no. 3; pp. 490 - 495
• Main Authors: VanBlargan, Laura A., Errico, John M., Halfmann, Peter J., Zost, Seth J., Crowe, James E., Purcell, Lisa A., Kawaoka, Yoshihiro, Corti, Davide, Fremont, Daved H., Diamond, Michael S.
• Format: Journal Article
• Language: English
• Published: New York Nature Publishing Group US 01.03.2022; Nature Publishing Group
• Subjects: 631/326/596/2558; 631/326/596/4130; Antibodies, Monoclonal - pharmacology; Antibodies, Monoclonal - therapeutic use; Antibodies, Monoclonal, Humanized; Antibodies, Neutralizing - therapeutic use; Antibodies, Viral - therapeutic use; Biomedical and Life Sciences; Biomedicine; Biotechnology; Cancer Research; Coronaviruses; COVID-19; COVID-19 Drug Treatment; Humans; Immunoglobulin G; Infectious Diseases; Metabolic Diseases; Molecular Medicine; Monoclonal antibodies; Mutation; Neurosciences; Neutralization; SARS-CoV-2; Severe acute respiratory syndrome coronavirus 2; Spike Glycoprotein, Coronavirus - genetics; Spike protein; Viral diseases; Viruses

The emergence of the highly transmissible B.1.1.529 Omicron variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is concerning for antibody countermeasure efficacy because of the number of mutations in the spike protein. In this study, we tested a panel of anti-receptor-binding do...